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Introduction
Diabetes mellitus is growing in pandemic proportions 
and is associated with significant morbidity, mortality, and 
health care expenditures. It affects more than 29 million 
people in the United States (9.3% population), a trend if 
continues can result in every third adult having diabetes 
mellitus by 2050 (1). It affects around 415 million people 
worldwide, a number that is projected to increase to 
642 million worldwide (12% population) by 2040, affecting 
one in every 10 adults (2). In the Unites States diabetes 
mellitus is the seventh leading cause of death, a number 
that is underreported (1). Per the International Diabetes 
Federation, 1 person dies from diabetes mellitus every 
6 seconds around the world (2). The total cost of diabetes 
mellitus is estimated to be more than $245 billion in the 
United States and around $673 billion worldwide (1,2). 
Type 2 diabetes mellitus (T2DM) is the most common, 
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accounting for about 90–95% of diagnosed diabetes in 
United States adults (1).
Individuals with T2DM have a 2- to 3-fold increased 
risk of cardiovascular (CV) events compared with their 
non-diabetic counterparts, and CV mortality is responsible 
for around 80% of the mortality in T2DM (3,4). A meta-
analysis showed that the relative risk (RR) for coronary 
heart disease or stroke has been estimated at 1.18% for 
every 1% increase in glycated hemoglobin (HbA1C) (5). 
Available evidence suggests that hyperglycemia is a weak 
risk factor for CV events, and tight glycemic control had 
very little effect on reducing macrovascular events and CV-
related death (6,7). Intensive glycemic control increased 
mortality without reducing CV events (8). In addition to 
hyperglycemia, individuals with T2DM can have other 
features of insulin resistance-metabolic syndrome like 
hypertension, lipid abnormalities, and obesity which are all 
associated with increased CV disease and stroke risk even 
in the absence of T2DM (9,10). Thus, the management of 
T2DM patients should include control of CV risk factors in 
addition to hyperglycemia to improve both macrovascular 
and microvascular complications and resulting morbidity 
and mortality. With the increasing prevalence of T2DM 
and metabolic syndrome, and associated significant CV 
disease and mortality, there is a need for novel diabetic 
medications which have a role in improving metabolic risk 
factors in addition to hyperglycemia.
Metformin and pioglitazone has been shown to have 
a CV protective benefit via their effect on improving 
lipid profile, weight, and blood pressure (BP), and insulin 
sensitivity (11,12). Metformin decreases gluconeogenesis in 
liver, increases insulin sensitivity, and improves the efficacy 
of endogenous insulin (11). A meta-analysis suggesting that 
rosiglitazone was associated with significantly increased risk 
of myocardial infarction (MI) and CV-related death led to 
an intense debate about the CV safety of the antidiabetic 
drugs (13). This led to regulatory agencies requiring CV 
safety trials as part of the approval process for newer 
antidiabetic drugs (14,15). This review article will discuss 
the CV benefits of the newer incretin based therapies and 
sodium glucose cotransporter-2 (SGLT-2) inhibitors as 
observed in their CV safety trials.
Incretin based therapies
Incretins are insulinotropic intestinal hormones secreted 
into the blood by the enteroendocrine cells in response in 
oral glucose intake (16). These hormones then stimulate 
the secretion of insulin from the pancreatic ß-cells, a 
phenomenon called the incretin effect (16). Two incretins, 
glucose-dependent insulinotropic peptide and glucagon-like 
peptide 1 (GLP-1) were characterized and studied in human 
beings. Both the incretin hormones are rapidly degraded by 
dipeptidyl peptidase-4 (DPP-4) in the circulation (16). The 
insulinotropic effect of glucose-dependent insulinotropic 
peptide is deficient in patients with T2DM thereby limiting 
it from being a therapeutic target (16). The incretin effect of 
GLP-1 is better preserved in T2DM patients, thus making 
it a potential therapeutic target in this population (16). 
GLP-1 also inhibits gastric emptying, decreases appetite, 
inhibits glucagon secretion from pancreatic α-cells via a 
paracrine effect medicated by somatostatin release, and 
slows the rate of endogenous glucose production, all of 
which improve glycemic control in T2DM (16). Two 
approaches were devised to augment the beneficial role on 
incretins in T2DM. One approach is the use of exogenous 
GLP-1 agonists resistant to degradation by DPP-4. The 
other approach is the use of DPP-4 inhibitors to enhance 
the half-life and effects of endogenous GLP-1.
GLP-1 receptor agonists (RAs)
Currently available RAs include albiglutide once weekly, 
dulaglutide once weekly, exenatide twice daily, extended 
release exenatide once weekly, liraglutide once daily, and 
lixisenatide once daily. A comprehensive review of all 
head-to-head data indicates that liraglutide followed by 
exenatide appear to offer the best HbA1C (approximately 
1–2%) and weight reduction (17). Retrospective analyses 
of data suggested a possible reduced likelihood of having 
a CV event over a 1- to 4-year period among patients 
who were treated with exenatide twice daily compared 
with other glucose-lowering agents (18). In 2 recent large 
randomized controlled trials, the GLP-1 RAs liraglutide 
and semaglutide showed remarkable CV benefit compared 
to placebo when added to patients with T2DM and high 
CV risk (19,20). The perceived CV benefit of GLP-1 RAs 
can be attributed to the extra-pancreatic pleotropic effects 
of GLP-1 on the CV system, and the favorable impact of 
GLP-1 RAs on important non-glycemic CV risk factors like 
BP, weight, and lipid profile.
GLP-1 receptors are present on rodent and human 
cardiac myocytes, endothelial cells, and vascular smooth 
muscle cells (16).  Numerous  in vitro studies have 
demonstrated the protective effects of liraglutide and 
exenatide on endothelial cells independent of GLP-
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1 RA glycemic and weight reduction effects (21,22). 
The favorable effects on endothelial cells is mediated 
via activation of endothelial nitric oxide synthase, and 
inhibition of tumor necrosis factor alpha, plasminogen 
activator inhibitor-1, various growth factors, and adhesion 
molecules. Through these GLP-1 receptor-dependent 
mechanisms, GLP-1 RAs improve endothelial dysfunction 
and attenuate atherosclerosis and intimal hyperplasia. 
Exenatide and liraglutide lowered BP, reduced myocardial 
infarct size, and improved systolic and diastolic cardiac 
function in various animal models of ischemia-reperfusion 
injury and congestive heart failure (HF) (16,21,22). 
Infusion of exenatide during two consecutive days in men 
with T2DM and HF led to significantly increased cardiac 
index and decreased pulmonary capillary wedge pressure 
compared to placebo (23) (Figure 1).
The CV benefit of GLP-1 RAs in terms of risk factor 
improvement compared with placebo and most standard 
anti-diabetic agents was observed in human clinical studies. 
Treatment with liraglutide or exenatide was associated 
with modest systolic BP reductions (21). In a meta-analysis 
of 33 trials (12,469 patients) in which 41% patients were 
treated with liraglutide and the rest with exenatide, GLP-
1 RA treatment achieved a greater systolic BP reduction 
than comparator therapy [weighted mean difference of 
2.22 mmHg, 95% confidence interval (CI): −2.97 to −1.47] 
independent of baseline BP, weight loss, or improvement 
in HbA1C (24). Improvements in lipid profile by reducing 
triglycerides, apolipoproteins B-48, free fatty acids, low-
density lipoprotein cholesterol (LDL-C), and total 
cholesterol was observed with GLP-1 RA treatment (21). 
In a meta-analysis of 35 trials, GLP-1 RAs were associated 
with modest reductions in LDL-C, total cholesterol, and 
triglycerides but no significant improvement in high density 
lipoprotein cholesterol (HDL-C) (25). Clinical studies 
of liraglutide and exenatide also demonstrated significant 
weight loss, and improvements in CV risk biomarkers like 
plasminogen activator inhibitor-1 and high-sensitivity 
C-reactive protein (16,21).
The Evaluation of Lixisenatide in Acute Coronary 
Figure 1 Approach to patients with type 2 diabetes mellitus (T2DM). Role of glucagon like peptide-1 (GLP-1) agonists and sodium glucose 
contransporter-2 (SGLT-2) inhibitors. CVD, cardiovascular disease; eNOS, endothelial nitric oxide synthase; TNF, tumor necrosis factor; 
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Syndrome (ELIXA) trial randomized 606 T2DM patients 
who had a MI or who had been hospitalized for unstable 
angina within the previous 180 days to receive lixisenatide 
or placebo in addition to locally determined standards 
of care (26). Primary end-point was a composite of CV 
death, MI, stroke, or hospitalization for unstable angina. At 
25-month follow up, the primary end-point event occurred 
in 13.4% patients in the lixisenatide group and in 13.2% in 
the placebo group [hazard ratio (HR) 1.02; 95% CI: 0.89 
to 1.17], which showed the noninferiority of lixisenatide to 
placebo (P<0.001) but did not show superiority (P=0.81). 
There were no significant between-group differences in the 
rate of hospitalization for HF (HR in the lixisenatide group, 
0.96; 95% CI: 0.75 to 1.23) or the rate of death (HR, 0.94; 
95% CI: 0.78 to 1.13). The authors concluded that the 
addition of lixisenatide to usual care did not significantly 
alter the rate of major CV events or other serious adverse 
events (26).
The Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results (LEADER) 
trial is a double-blind, placebo controlled trial that 
randomized 9340 T2DM patients at high CV risk to either 
1.8 mg (or the maximum tolerated dose) of liraglutide or 
matching placebo once daily as a subcutaneous injection in 
addition to standard care (19). High CV risk was defined 
as age ≥50 years with at least one CV coexisting condition 
(coronary heart disease, cerebrovascular disease, peripheral 
vascular disease, chronic kidney disease of stage 3 or 
greater, or chronic HF of New York Heart Association 
class II or III) or an age ≥60 years with at least one CV 
risk factor (microalbuminuria or proteinuria, hypertension 
and left ventricular hypertrophy, left ventricular systolic or 
diastolic dysfunction, or an ankle-brachial index of less than 
0.9). The primary composite outcome in the time-to-event 
analysis was the first occurrence of death from CV causes, 
nonfatal MI, or nonfatal stroke. After a median follow up 
of 3.8 years, significantly fewer patients in the liraglutide 
group than in the placebo group experienced the primary 
outcome (13.0% vs. 14.9%; HR 0.87; 95% CI: 0.78 to 
0.97; P<0.001 for noninferiority; P=0.01 for superiority), 
CV-related death (4.7% vs. 6.0%; HR 0.78; 95% CI: 0.66 
to 0.93; P=0.007), or all-cause death (8.2% vs. 9.6%; HR 
0.85; 95% CI: 0.74 to 0.97; P=0.02). In subgroup analysis, 
the CV benefit of liraglutide was more apparent in patients 
with established CV disease compared to placebo (14% vs. 
16.7%; HR 0.83; 95% CI: 0.74 to 0.93; P=0.04).
The liraglutide group had non-significantly lower 
frequencies  of  nonfata l  MI,  nonfata l  s troke,  HF 
hospitalization rate, and acute pancreatitis. At 36 months, 
the liraglutide group had improved CV risk factor profile 
in terms of higher weight loss (mean 2.3 kg; 95% CI: 2.5 to 
2.0), lower systolic BP (1.2 mmHg; 95% CI: 1.9 to 0.5), and 
a lower rate of nephropathy events (1.5 vs. 1.9 events per 
100 patient-years of observation; HR 0.78; 95% CI: 0.67 
to 0.92; P=0.003). The heart rate was 3.0 beats per minute 
(95% CI: 2.5 to 3.4) higher in the liraglutide group (19). 
The composite outcome of renal or retinal microvascular 
events was lower in the liraglutide group than in the 
placebo group (HR, 0.84; 95% CI: 0.73 to 0.97; P=0.02), a 
difference that was driven by a lower rate of nephropathy 
events in the liraglutide group (1.5 vs. 1.9 events per 100 
patient-years of observation; HR, 0.78; 95% CI: 0.67 
to 0.92; P=0.003). Retinopathy events were numerically 
higher in the liraglutide group (0.6 vs. 0.5 events per 100 
patient-years; HR, 1.15; 95% CI: 0.87 to 1.52; P=0.33) (19). 
Hypoglycemic events and gastrointestinal side effects 
(nausea, vomiting, diarrhea, abdominal discomfort, 
cholelithiasis, and acute cholecystitis) were significantly 
more frequent in the liraglutide group (19).
Semaglutide, a GLP-1 analogue with an extended half-
life of approximately 1 week is currently in development 
but not yet approved for the T2DM. The Trial to Evaluate 
Cardiovascular and Other Long-term Outcomes with 
Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) 
randomized 3,297 T2DM patients with either CV disease 
(89.3%) or chronic kidney disease (10.7%) to once-weekly 
subcutaneous semaglutide (0.5 or 1.0 mg) or placebo for 
104 weeks in addition to standard-care regimen (20). The 
primary composite outcome was the first occurrence of 
CV death, nonfatal MI, or nonfatal stroke. After a median 
follow up of 2.1 years, the primary outcome (6.6% in 
semaglutide group vs. 8.9% in placebo group; HR, 0.74; 
95% CI: 0.58 to 0.95; P<0.001 for noninferiority) occurred 
in significantly fewer semaglutide patients than placebo 
patients. There were significantly fewer nonfatal stroke 
events (1.6% vs. 2.7%; HR, 0.61; 95% CI: 0.38 to 0.99; 
P=0.04) and numerically fewer nonfatal MI events (2.9% 
vs. 3.9%; HR 0.74; 95% CI: 0.51 to 1.08; P=0.12) in the 
semaglutide group. Rates of CV-related death were similar 
in the two groups. The mean HbA1C in the semaglutide 
group, as compared with the placebo group, was 0.7 
percentage points lower in the group receiving 0.5 mg 
and 1.0 percentage point lower in the group receiving 
1.0 mg (estimated treatment difference) (P<0.001 for both 
comparisons). At 104 weeks, the semaglutide group had 
improved CV risk factor profile in terms of higher mean 
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weight loss (2.9 kg lower in the group receiving 0.5 mg 
and 4.3 kg lower in the group receiving 1.0 mg; P<0.001 
for both comparisons), lower mean systolic BP (1.3 mmHg 
lower in the group receiving 0.5 mg, P=0.10; and 2.6 mmHg 
lower in the group receiving 1.0 mg, P<0.001).
The semaglutide group had a lower rate of nephropathy 
events (3.8% vs. 6.1%; HR 0.64; 95% CI: 0.46 to 0.88; 
P=0.005). The mean heart rate was 2.0 bpm higher in the 
group receiving 0.5 mg semaglutide and 2.5 bpm higher 
in the group receiving 1.0 mg semaglutide (P<0.001 for 
both comparisons) compared to placebo (20). Diabetic 
retinopathy complications occurred in more semaglutide 
treated patients (3% vs 1.8%; HR 1.76; 95% CI: 1.11 to 
2.78; P=0.02), and were seen very early in the trial (20). 
Although the overall number of retinopathy events was 
low, there was an unexpected higher rate of retinopathy 
complications (vitreous hemorrhage, blindness, or 
the need for treatment with an intravitreal agent or 
photocoagulation) in the semaglutide group. It must be 
reminded that SUSTAIN-6 is a preapproval trial with a 
relatively short duration (2.1 years) designed to test the 
non-inferiority of semaglutide compared to placebo in 
influencing CV events, but not to investigate the superiority 
of semaglutide in reducing CV events. Results from this 
trial are encouraging and hypothesis generating for future 
research.
DPP-4 inhibitors
DPP-4 inhibitors are oral diabetic medications that prevent 
the peripheral inactivation of incretins by DPP-4, resulting 
in increased half-life, and extended insulinotropic and 
other actions of GLP-1 in T2DM patients (27). Currently 
approved DPP-4 inhibitors are sitagliptin, saxagliptin, 
linagliptin, alogliptin, and vildagliptin. DPP-4 has many 
substrates and thus inhibition of DPP-4 may have diverse 
effects in addition to prolongation of incretin effect. DPP-4 
can also degrade inflammatory chemokines, neuropeptides, 
and vasodilatory/fibrinolytic peptides like substance P and 
bradykinin (27). Although available data from early animal 
and human studies showed a favorable effect of DPP-
4 inhibition on atherosclerosis, the effects on endothelial 
function, vasodilatation, cardiac remodeling, and cardiac 
function are inconsistent (27,28). DPP-4 inhibition was 
associated with improved glycemic control, improved total 
cholesterol and triglyceride levels, and weight neutrality 
(27,29). The effects of DPP-4 inhibition on CV disease risk 
factors, cardiac function, and vascular repair likely represent 
contributions from and a balance of both GLP-1-dependent 
actions of DPP-4 inhibitors as well as mechanisms 
independent of GLP-1 (27). Recent large clinical trials have 
confirmed the safety and neutral effect of DPP-4 inhibitors 
on CV outcomes.
The Saxagliptin Assessment of Vascular Outcomes 
recorded in patients with diabetes mellitus-Thrombolysis 
in Myocardial Infarction 53 (SAVOR-TIMI 53) study 
randomized 16,492 patients with T2DM with established 
CV disease or multiple risk factors for vascular disease, 
to receive either daily saxagliptin or placebo in addition 
to standard diabetic and CV disease therapy (30). At 
median follow up of 2.1 years, saxagliptin did not increase 
or decrease the risk of the primary composite end-point 
of CV death, non-fatal MI or non-fatal ischemic stroke, 
compared with placebo (HR, 1.00; 95% CI: 0.89 to 1.12; 
P<0.001 for non-inferiority and P=0.99 for superiority). 
The occurrence of the major secondary end-point of a 
composite of CV death, MI, stroke, hospitalization for 
unstable angina, coronary revascularization, or HF was 
similar between the two groups (12.8% in saxagliptin group 
vs. 12.4% in placebo group; HR, 1.02; 95% CI: 0.94 to 1.11; 
P=0.66). More patients in the saxagliptin group than in the 
placebo group were hospitalized for HF (3.5% vs. 2.8%; 
HR, 1.27; 95% CI: 1.07 to 1.51; P=0.007) (30). A meta-
analysis of randomized trials of DPP-4 inhibitors showed 
that saxagliptin was significantly associated with a 21% 
increased risk of HF (RR, 1.215; 95% CI: 1.028 to 1.437; 
P=0.022) (31). The EXAmination of CV outcoMes with 
alogliptIN versus standard of carE (EXAMINE) trial 
randomized 5,380 T2DM patients with either an acute 
MI or unstable angina requiring hospitalization within the 
previous 15 to 90 days to receive alogliptin or placebo in 
addition to existing antihyperglycemic and CV drug therapy 
for a median follow up of 40 months (32). At 18-month 
follow up, alogliptin did not increase or decrease the risk 
of the primary composite end-point of CV death, non-
fatal MI or non-fatal stroke, compared with placebo (11.3% 
vs. 11.8%; HR, 0.96; upper boundary of the one-sided 
repeated CI, 1.16; P<0.001 for non-inferiority; P = 0.32 
for superiority). The analysis of the principal secondary 
end-point of death from CV causes, nonfatal MI, nonfatal 
stroke, or urgent revascularization due to unstable angina 
showed no significant difference between the alogliptin 
group and the placebo group (12.7% vs. 13.4%; HR, 0.95; 
upper boundary of the one-sided repeated CI, 1.14) (32). In 
a post hoc analysis, alogliptin did not significantly increase 
the rates of HF hospitalization compared to placebo 
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although a numerical increase was noted (3.9% vs. 3.3%; 
HR, 1.19; 95% CI: 0.90 to 1.58) (33). Alogliptin had no 
effect on composite events of CV and hospital admission 
for HF in a post hoc analysis (HR 1·00; 95% CI: 0.82 to 
1.21) and results did not differ by baseline b-type natriuretic 
peptide concentration (34). An increase in hospitalization 
for HF with alogliptin was noted in patients without a prior 
history of HF (2.2% with alogliptin vs. 1.3% with placebo; 
HR, 1.76; P=0.026) (34). Rates of CV death were similar 
between alogliptin and placebo (4.1% vs. 4.9%, HR 0.85; 
95% CI: 0.66 to 1.10) (35).
The Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin (TECOS) evaluated the long-term CV safety 
of the DPP-4 sitagliptin in T2DM patient with CV 
disease (36). TECOS randomized 14,671 T2DM patients 
with established CV disease (history of major coronary 
artery disease, ischemic cerebrovascular disease, or 
atherosclerotic peripheral arterial disease) to either daily 
oral sitagliptin or matching placebo in addition to existing 
therapy (36). At median follow up of 3 years, sitagliptin 
was noninferior to placebo for the primary composite 
end-point of CV death, nonfatal MI, nonfatal stroke, or 
hospitalization for unstable angina (11.4% vs. 11.6%; HR, 
0.98; 95% CI: 0.88 to 1.09; P<0.001; HR in the intention-
to-treat analysis, 0.98; 95% CI: 0.89 to 1.08; P=0.65 for 
superiority). Similarly, sitagliptin was noninferior to placebo 
for the secondary composite end-point of first confirmed 
event of CV death, nonfatal MI, or nonfatal stroke (HR 
in the per-protocol analysis, 0.99; 95% CI: 0.89 to 1.11; 
P<0.001 for noninferiority; HR in the intention-to-treat 
analysis, 0.99; 95% CI: 0.89 to 1.10; P=0.84 for superiority). 
Sitagliptin did not increase the rates of HF hospitalization 
(1.07 per 100 person-years vs. 1.09 per 100 person-years; 
HR, 1.00; 95% CI: 0.83 to 1.20; P=0.98) (36). The TECOS 
confirmed that adding sitagliptin to usual care did not 
appear to increase the risk of major adverse CV events, 
especially hospitalization for HF, or other adverse events.
In a pooled analysis of randomized trials in T2DM 
patients comparing linagliptin to either placebo or an active 
comparator medication, linagliptin was not associated with 
an increased CV risk (37). The 27% increased risk of HF 
hospitalization with the DPP-4 inhibitor saxagliptin as 
observed in the SAVOR-TIMI 53 trial was not replicated 
in the EXAMINE or the TECOS trials with alogliptin and 
sitagliptin, respectively (38). The Canadian Network for 
Observational Drug Effect Studies (CNODES) investigators 
examined existing data from multiple cohorts of patients 
(total of 1,499,650 patients, with 29,741 hospitalized for 
HF) to determine whether the use of incretin-based drugs, 
as compared with oral antidiabetic-drug combinations, 
in routine clinical practice is associated with an increased 
risk of HF (38). In this retrospective observational 
analysis, incretin-based therapy did not increase the rate of 
hospitalization for HF among patients with a history of HF 
(HR, 0.86; 95% CI: 0.62 to 1.19) or among those without 
a history of HF (HR, 0.82; 95% CI: 0.67 to 1.00). These 
results were similar for both DPP-4 inhibitors and GLP-1 
RAs. The investigators concluded that incretin-based drugs 
were not associated with an increased risk of hospitalization 
for HF, as compared with commonly used combinations of 
oral antidiabetic drugs (38).
In a meta-analysis of 54 randomized controlled trials of 
DPP-4 inhibitors in 74,737 participants with a minimum 
follow-up of 12 weeks, DPP-4 inhibitors were not associated 
with an increased risk of HF compared to comparators (RR 
1.106; 95% CI: 0.995 to 1.228; P=0.062) (31). The authors 
noted a differential effect of each DPP-4 inhibitor on the 
risk of HF. Use of saxagliptin significantly increased the 
risk of HF by 21% especially among patients with high CV 
risk (RR 1.215; 95% CI: 1.028 to 1.437; P=0.022), while 
others were not associated with an increased HF risk (31). 
Age ≥65 years, diabetes duration of ≥10 years and BMI 
≥30 kg/m2 were associated with an increased risk of HF 
among patients using saxagliptin (31). Based on available 
data, the risk of HF with DPP-4 inhibitors is of definitive 
concern and appears to be drug-specific. After reviewing 
the data from SAVOR-TIMI 53 and EXAMINE trials, the 
FDA found an increased risk of HF with saxagliptin and 
alogliptin particularly in patients with underlying heart or 
kidney disease and announced safety warnings to be added 
to the labels of these two DPP-4 inhibitors (39).
SGLT2 inhibitors
SGLT-2 inhibitors are a novel class of medications that 
improve glycemic control via reduced glucose reabsorption 
in the renal proximal tubule resulting in glycosuria (40). 
SGLT-2 is present in segment 1 of the proximal tubule 
and normally accounts for around 90% of the glucose 
reuptake (40). As SGLT-2 expression is highly specific 
for the kidneys, SGLT-2 inhibitors should not affect 
glucose transport in other tissues (41). SGLT-2 inhibitors 
act independent of insulin secretion, severity of insulin 
resistance, and pancreatic ß-cell failure (40). The above 
unique mechanisms are responsible for the very low 
potential of SGLT-2 inhibitors to cause hypoglycemia and 
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suggest that they may be effective across the spectrum of 
T2DM disease progression. As they act within the tubule, 
reduced glomerular filtration rate in chronic kidney disease 
can reduce the efficacy and safety of SGLT-2 inhibitors 
(40,41). Canagliflozin, dapagliflozin, and empagliflozin are 
some of the approved SGLT-2 inhibitors.
SGLT-2 inhibitors improve both glycemic and non-
glycemic risk factors in T2DM patients. They induce urinary 
glucose losses around 40–80 g/day, resulting in decent 
glycemic control (HbA1c reduction around 0.7%) (42). 
This corresponds to around 200–300 kilocalories daily 
which can result in a 2–3 kg body weight loss over 24–52 
weeks (40). Most weight loss associated with SGLT-
2 inhibition was due to reduction in visceral fat which is 
associated with increased risk of T2DM, CV complications 
and overall mortality (40). SGLT-2 inhibitors showed a 
consistent BP lowering effect, more systolic than diastolic, 
without a compensatory increase in pulse rate, in multiple 
clinical studies (43,44). The mechanism of BP reduction is 
not entirely clear. Possible mechanisms include the osmotic 
diuretic effect, weight reduction, and a possible direct 
vascular effect via reducing arterial stiffness (40,44). In a 
meta-analysis of 27 randomized controlled trials (n=12,960 
participants), SGLT-2 inhibitors significantly reduced both 
systolic BP (weighted mean difference of 4.0 mmHg) and 
diastolic BP (weighted mean difference of 1.6 mmHg) 
from baseline (43). SGLT-2 inhibitors were associated 
with a small increase in both HDL-C and LDL-C levels 
with concomitant reductions in triglyceride levels, the 
effect of which on CV events is not very clear at this time 
(40,45). SGLT-2 inhibition is also associated with reduced 
glomerular hyperfiltration and urinary albumin excretion 
which might suggest the nephroprotective effect of this 
class of drugs (40 (Figure 1).
Several analyses of pooled data suggest that SGLT-
2 inhibitors do not appear to increase CV risk (40). The 
best available data on the effects of SGLT-2 inhibition on 
CV outcomes comes from the BI 10773 (Empagliflozin) 
Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients (EMPA-REG OUTCOME) study (46). 
The EMPA-REG OUTCOME trial randomized 7020 
T2DM patient with established CV disease to receive 
either 10 or 25 mg of empagliflozin or placebo once daily 
in addition to standard anti-hyperglycemic and CV disease 
therapies (46). The primary outcome was a composite of 
death from CV causes, nonfatal MI (excluding silent MI), 
or nonfatal stroke. After a median 3.1 years, significantly 
fewer patients in the empagliflozin group than in the 
placebo group experienced the primary outcome (10.5% 
vs. 12.1%; HR in the empagliflozin group, 0.86; 95.02% 
CI: 0.74 to 0.99; P=0.04 for superiority), which was largely 
driven by the significantly lower CV-related death (3.7% 
vs. 5.9%; 38% RR reduction; HR, 0.62; 95% CI: 0.49 to 
0.77; P<0.001). There were no significant between-group 
differences in the occurrence of MI or stroke (P=0.22). The 
empagliflozin group had lower rates of hospitalization for 
HF (2.7% vs. 4.1% in placebo group; 35% RR reduction), 
and death from any cause (5.7% vs. 8.3% in placebo 
group; 32% RR reduction; HR, 0.68; 95% CI: 0.57 to 
0.82, P<0.001). The key secondary outcome which was a 
composite of the primary outcome plus hospitalization for 
unstable angina occurred in fewer empagliflozin treated 
patients (12.8% vs. 14.3 % in the placebo group; HR, 
0.89; 95% CI: 0.78 to 1.01; P<0.001 for noninferiority 
and P=0.08 for superiority). Empagliflozin, as compared 
with placebo, was associated with small reductions in 
weight, waist circumference, uric acid level, and systolic 
and diastolic BP with no increase in heart rate and small 
increases in both LDL-C and HDL-C (46).
Studies examining renal outcomes with SGLT-2 
inhibitors were also reported. In a study of 1450 T2DM 
patients on metformin randomly assigned to either 
canagliflozin or glimepiride, canagliflozin treated patients 
had significantly less decline in estimated glomerular 
filtration rate and greater reduction in urinary albumin-
to-creatinine ratio compared to glimepiride (47). The 
authors concluded that canagliflozin, compared with 
glimepiride, slowed the progression of renal disease over 
2 years in patients with T2DM, and canagliflozin may 
confer renoprotective effects independently of its glycemic 
effects (47). This study was not designed nor powered 
to compare the renoprotective effects of canagliflozin 
versus glimepiride, so the results should be interpreted 
as hypothesis-generating (47). Results of a prespecified 
secondary end-point of the EMPA-REG OUTCOME trial 
to evaluate the effects of empagliflozin on microvascular 
outcomes were later published (48). Among patients with 
glomerular filtration rates of ≥30 mL/minute/1.73 m2, 
incident or worsening nephropathy occurred in 12.7% 
patients in the empagliflozin group and in 18.8% patients 
in the placebo group (HR in the empagliflozin group, 0.61; 
95% CI: 0.53 to 0.70; P<0.001), doubling of the serum 
creatinine level occurred in 1.5% in the empagliflozin 
group and in 2.6% in the placebo group (significant RR 
reduction of 44%), renal-replacement therapy was initiated 
in 0.3% in the empagliflozin group and in 0.6% in the 
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placebo group (55% lower RR). Empagliflozin did not 
prevent development of microalbuminuria (48). Studies 
evaluating the CV benefit of canagliflozin [Canagliflozin 
Cardiovascular Assessment Study (CANVAS)], dapagliflozin 
[The Multicenter Trial  to Evaluate the Effect of 
Dapagliflozin on the Incidence of Cardiovascular Events 
(DECLARE-TIMI58)], and ertugliflozin in T2DM patients 
are currently undergoing (49-51).
Update on pioglitazone
Pioglitazone, a thiazolidinedione, acts by regulating 
peroxisome proliferator-activated receptor-gamma mediated 
gene expression resulting in increased insulin sensitivity and 
glucose utilization, and decreased glucose production (12). 
Pioglitazone has been shown to have a CV protective 
benefit in diabetic patients via its effect on improving lipid 
profile, weight, BP, and insulin sensitivity (12). The CV 
effects of pioglitazone in non-diabetic patients with insulin 
resistance has been recently investigated. , In the recent, 
double-blind, controlled, Insulin Resistance Intervention 
after Stroke (IRIS) study which randomized 3,876 non-
diabetic patients with insulin resistance and a recent 
ischemic stroke or transient ischemic attack to receive 
either pioglitazone or placebo, pioglitazone reduced the 
primary outcome of fatal or nonfatal stroke or MI (9% vs. 
11.8% in the placebo group; HR in the pioglitazone group, 
0.76; 95% CI: 0.62 to 0.93; P=0.007), without reducing all-
cause mortality at 4.8-year follow-up (52). Pioglitazone 
also reduced incident diabetes mellitus (3.8% vs. 7.7% 
in the placebo group; HR, 0.48; 95% CI: 0.33 to 0.69; 
P<0.001) (52). These findings further support the fact that 
improving metabolic control irrespective of the presence on 
diabetes mellitus has an important role to play in improving 
atherosclerotic risk factors and resultant CV disease in high 
risk patients.
Role of incretin based therapies and SGLT-2 
inhibition in the future of T2DM and CV disease
Recent years have been exciting for both cardiologists and 
endocrinologists with the introduction of newer therapies 
for T2DM with observed CV benefits in large randomized 
trials. The primary outcome in these trials was a CV 
composite of CV-related death, non-fatal MI, or nonfatal 
stroke. In the LEADER trial, the GLP-1 RA liraglutide 
significantly reduced the primary outcome, largely driven 
by improvements in CV-related death and all-cause 
mortality (19). In the SUSTAIN-6 trial, semaglutide 
significantly improved the primary outcome, an effect 
that was largely driven by reduction of non-fatal stroke 
events (20). In both the trials, there were numerically 
fewer non-fatal MI events (19,20). Results from these 
trials suggest that the CV benefit of GLP-1 RAs in T2DM 
patients was driven by improvements in vascular risk factors 
and atherosclerosis rather than improving HF. GLP-1 RAs 
have extra-pancreatic actions on the CV system which are 
probably responsible for the improvements noted in CV 
risk factors like weight, BP, and lipid parameters. Although 
the DPP-4 inhibitors extend the actions of endogenous 
incretins, they appear to have diverse actions on other 
inflammatory and metabolic pathways which could have 
negated the CV protective role of prolonging GLP-1 
activity. However, DPP-4 inhibitors were proven to be safe 
from a CV standpoint based on the available recent data 
despite concerns regarding increased HF risk prompting 
the issue of FDA warnings (30,32,33,36-38).
In the EMPA-REG OUTCOME trial, empagliflozin, 
with its renal-specific actions, dramatically reduced the 
risk of CV deaths, HF hospitalizations, and all-cause 
mortality with RR reductions of 30–40% in these outcomes, 
prompting cardiologists to prescribe this medication to 
T2DM patients at risk for HF (46). Significant improvement 
in primary outcome from this trial was largely driven by 
reduced mortality and HF hospitalization rate rather than 
prevention of vascular/atherosclerotic events. The reduced 
HF hospitalizations could be from the diuretic action and 
BP lowering effect of empagliflozin (53). This mechanism of 
action, along with proven benefit in a large randomized trial, 
can make empagliflozin an important component of T2DM 
therapy in patients with HF with reduced ejection fraction. 
Empagliflozin caused slight improvements in other CV risk 
factors like weight, BP, and lipid profiles (46). Interestingly, 
in this trial, improvement in the primary outcome and HF 
hospitalizations was apparent very early in the course of the 
trial at around 3 months from randomization and persisted 
throughout the duration of the study (46). Improvements 
in mortality occurred early and improved across the 3-year 
study period (46). Also important are the nephroprotective 
actions of SGLT-2 inhibitors as observed with canagliflozin 
and empagliflozin. Nephroprotection is important in 
patients with CV disease and HF as worsening kidney 
function can mutually worsen HF. Further larger studies 
which are currently undergoing will provide clarity on the 
nephroprotective actions of SGLT-2 inhibitors (40). Given 
the possibility of differential improvements in CV disease 
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from GLP-1 agonists and SGLT-2 inhibitors, future research 
should include trials to evaluate the beneficial effects of the 
combination of these drugs to improve atherosclerotic and 
HF outcomes (Figure 1).
Conclusions
T2DM is growing in pandemic proportions and is likely to 
affect a large proportion of adult population worldwide in the 
coming years. Being associated with significant morbidity, 
mortality, and health care expenditures, it is imperative to 
control the responsible risk factors. Metabolic and CV risks 
pose a major threat in the T2DM population accounting for 
its major healthcare implications. Emerging evidence suggest 
that in T2DM patients, hyperglycemia plays a little role in 
the progression of CV disease, and metabolic risk factors like 
insulin resistance, hypertension, obesity, and dyslipidemia 
are the major culprits in the initiation and progression of 
CV disease. Hence it is imperative to adopt a holistic risk 
factor control approach when managing a T2DM patient. 
Interestingly, newer anti-hyperglycemic medications like 
the GLP-1 RAs and SGLT-2 inhibitors showed promise 
in recent clinical trials in terms of providing CV benefit 
irrespective of the glycemic control. However, these findings 
were largely apparent in patients with established CV disease 
as they were more represented in the randomized controlled 
trials evaluating these drugs. Currently undergoing larger 
trials will provide more information and clarity on the CV 
protective role of these newer medications. Studies evaluating 
the CV protective role of the newer T2DM medications 
in patients without established CV disease are necessary to 
establish the role of these drugs in the treatment paradigm 
of T2DM. As T2DM or insulin resistance syndrome, CV 
disease, and HF are frequently coexistent, it would be 
interesting to design studies evaluating the combinations of 
GLP-1 RAs, SGLT-2 inhibitors, and pioglitazone in T2DM 
patient at an elevated CV risk, and in non-diabetic patients 
with insulin resistance to study the possible CV protective 
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